C
C

Financials • Citius Oncology

CTOR

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products.  In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

9/2023
2 financials
9/2024
Year
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
0
-21
-21
L
46
L
4
L
-7
-5
5
-12
L

To see all financials—including updated, you must be Premium.